Baird raised the firm’s price target on Cogent Biosciences (COGT) to $35 from $34 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results and noted Bezu regulatory progress ongoing across three indications.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
- Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
- Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
- Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year
- Cogent Biosciences sees cash runway into 2028